CARM

Carisma Therapeutics, Inc. (NASDAQ:CARM) is a clinical-stage biopharmaceutical company founded in 2016 and based in Philadelphia, Pennsylvania. The company was originally incorporated as CARMA Therapeutics Inc. before changing its name to Carisma Therapeutics in May 2017. Carisma went public in February 2014 and has established itself as a pioneer in developing chimeric antigen receptor (CAR) macrophage therapies for treating solid tumors. The company has formed strategic partnerships with major pharmaceutical companies, including a notable collaboration agreement with Moderna Inc.